期刊文献+

VEGF、COX-2在甲状腺癌中的表达及临床意义 被引量:4

Expression of VEGF,COX-2 in Thyroid Carcinoma and Its Clinical Significance
下载PDF
导出
摘要 目的探讨VEGF、COX-2在甲状腺癌肿的表达及其临床意义。方法采用免疫组化的方法,对71例甲状腺癌、53例甲状腺良性肿瘤、10例正常甲状腺组织VEGF、COX-2的表达进行检测,并将甲状腺癌的组织学分型、淋巴转移、病人年龄、性别进行对比分析。结果甲状腺癌、甲状腺良性肿瘤、正常甲状腺组织中VEGF的表达阳性率分别为77.5%,15.1%,11.1%,差异具有统计学意义(P<0.05),COX-2的表达阳性率分别为64.8%、13.2%、11.1%,差异具有统计学意义(P<0.05)。甲状腺癌中VEGF和COX-2的表达与组织病理分型和淋巴结转移比较的差异具有统计学意义(P<0.05);在乳头状癌、滤泡状癌、髓样癌、未分化癌中VEGF的表达阳性率分别为81.8%、68.8%、55.6%、92.3%,COX-2的表达阳性率分别为81.8%、88.2%、77.7%、92.3%。而与甲状腺癌患者的年龄、性别无关(P>0.05)。甲状腺癌中VEGF的表达和COX-2的表达呈正相关。结论 VEGF和COX-2在甲状腺癌的发生、发展中均起到重要作用,并且存在一定的协同作用,两者联合检测能为甲状腺癌的恶性程度以及预后判断上提供有力证据。 Objective To explore the expression of VEGF,COX -2 in thyroid carcinoma and its clinical significance. Methods Expression of VEGF, COX - 2 was detected in 71 cases with thyroid carcinoma,53 cases with thyroid adenomas, 10 cases of normal thyroid tissues by immunohistochemical method. The relationship between VEGF, COX -2 and thyroid carcinoma pathological type,lymph node metastasis status,age and gender was analyzed. Results Expression of VEGF in thyroid carcinoma,thyroid adenomas,normal thyroid tis- sues was 77.5% , 15.1% and 1 I. 1% respectively, which had significant difference ( P 〈 O. 05). Expression of COX - 2 in thyroid carci- noma,thyroid adenomas, normal thyroid tissues was 64.8% , 13.2% and 11. 1% respectively, which had significant difference (P 〈 0.05 ). The expression of VEGF ,COX - 2 was significant different with pathological type and lymph node metastasis status in thyroid car- cinoma(P 〈 0.05) , but there was no statistical difference among age and gender( P 〉 0.05). The VEGF expression in papillary thyroid carcinoma,follicular carcinomas,medullary carcinoma,undifferentiated carcinoma was 81.8% ,68.8% ,55.6% ,92.3% and COX - 2 ex- pression was 81.8% ,88.2% ,77.7% ,92.3%, respestively. Expression of VEGF was positively related to the expression of COX- 2. Conclusion VEGF,COX -2 play an important role in carcinogenesis and development of thyroid carcinoma. Combinded detection can provide valuable evidence for estimation of aggressive degree and progonosis.
出处 《医学研究杂志》 2012年第2期146-150,共5页 Journal of Medical Research
关键词 甲状腺癌 VEGF COX-2 免疫组化 Thyroid carcinoma VEGF COX - 2 Immunohistochemical
  • 相关文献

参考文献13

  • 1Huang SM,Lee JC,Wu TJ,et al.Clinical relevance of vascular en-dothelial growth factor for thyroid neoplasms[J].World J Surg,2001,25(3):302-306.
  • 2Tuttle RM,Fleisher M,Francis GL,et al.Serum vascular endothelialgrowth factor levels are elevated in metastatic differentiated thyroidcancer but not increased by short-term TSH stimulation[J].J ClinEndocrinol Metab,2002,87(4):1737-1742.
  • 3Poulaki V,Mitsiades CS,McMullan C,et al.Regulation of vascularendothelial growth factor expression by insulin-like growth factor I inthyroid carcinomas[J].J Clin Endocrinol Metab,2003,88(11):5392-5398.
  • 4Bass MB,Sherman SI,Schlumberger MJ,et al.Biomarkers as pre-dictors of response to treatment with motesanib in patients with pro-gressive advanced thyroid cancer[J].J Clin Endocrinol Metab,2010,95(11):5018-5027.
  • 5Gule MK,Chen Y,Sano D,et al.Targeted therapy of VEGFR2 andEGFR significantly inhibits growth of anaplastic thyroid cancer in anorthotopic murine model[J].Clin Cancer Res,2011,17(8):2281-2291.
  • 6Hsueh C,Lin JD,Wu IC,et al.Vascular endothelial growth factorsand angiopoietins in presentations and prognosis of papillary thyroidcarcinoma[J].J Surg Oncol,2011,103(5):395-399.
  • 7Siironen P,Ristimaki A,Narko K,et al.VEGF-C and COX-2 ex-pression in papillary thyroid cancer[J].Endocr Relat Cancer,2006,13(2):465-473.
  • 8Lee KJ,Jung YS,Kim WH,et al.Cyclooxygenase-2 expression inhuman thyroid disease[J].J Endocrinol Invest,2008,31(2):111-118.
  • 9Yates CM,Patel A,Oakley K,et al.Erythropoietin in thyroid cancer[J].J Endocrinol Invest,2006,29(4):320-329.
  • 10Siironen P,Louhimo J,Nordling S,et al.Prognostic factors in papil-lary thyroid cancer:an evaluation of 601 consecutive patients[J].Tumour Biol,2005,26(2):57-64.

二级参考文献19

共引文献10

同被引文献40

  • 1刘疏影,狄娟,李铮,俞杨,刘子中,戴冀斌.核转录因子κB在神经干细胞中的作用及信号通路[J].解剖学研究,2010,32(4):286-290. 被引量:4
  • 2朱美琴,滕小玉,姜文奇,刘冬耕,张东生,周宁宁.乳腺癌病人血清HER-2/neu检测及其临床意义[J].中山大学学报(医学科学版),2007,28(6):678-682. 被引量:10
  • 3Park S,Koo JS,Kim MS,et al.Characteristics and outcomes according to molecular subtypes of breast cancer as classified by a panel of four biomarkers using immunohistochemistry[J].Breast,2012,21(1):50-57.
  • 4Tonra JR,Hicklin DJ.Targeting the vascular endothelial growth factor pathway in the treatment of human malignancy[J].Immunol Invest,2007,36(1):3-23.
  • 5Vidaurreta M,SdnchezMunoz R,Veganzones S,el al.Vascular enodothelial Smwth factor gene polymorphisms in patients with colorectal cancer[J].Rev Esp Enferm Dig,2010,102(1):20-31.
  • 6Bossung V,Harbeck N.Angiogenesis inhibitors in the management of breast cancer[J].Curr Opin Obstet Gynecol,2010,22(1):79-86.
  • 7Perou CM,Sorlie T,Eisen MB,et al.Molecular portraits of humanbreast tumours[J].Nature,2000,406(6797):747-775.
  • 8NielsenI TO,Hsu FD,Jensen K,et al. Immunohistochemical andclinical characterization of the basal-like subtype of invasivebreast carcinoma [J]. Clin Cancer Res, 2004, 10 (16):5367-5374.
  • 9Goldhirsch A,Wood WC,Coates AS,et al. Strategies for subtypes-dealing with the diversity of breast cancer: highlights of thest gallen international expert consensus on the primary therapy ofearly breast cancer 2011 [J]. Ann Oncol, 2011, 22 (8):1736-1747.
  • 10Singh B, Berry JA, Shoher A, et al. COX-2 overexpression increases motil- ity and invasion of breast cancer cells. Int J Oncol,2005,26 : 1393-1399.

引证文献4

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部